Loading...
•
Mar 31, 2025
ClearPoint Neuro Q1 2025 Earnings Report
ClearPoint Neuro reported record Q1 revenue driven by strong growth in navigation, biologics, and drug delivery products.
Key Takeaways
ClearPoint Neuro delivered an 11% year-over-year revenue increase in Q1 2025, with record revenue of $8.5 million. Growth was led by significant gains in consumables and single-use navigation and therapy products, offset slightly by lower capital equipment sales.
Revenue reached a record $8.5 million, up 11% YoY.
Neurosurgery navigation and therapy revenue rose 70% to $3.3 million.
Biologics and drug delivery revenue totaled $4.7 million, up 9%.
Capital equipment revenue declined 63% due to installation timing.
Revenue by Segment
Forward Guidance
ClearPoint reaffirmed its FY25 revenue guidance, reflecting confidence in product demand and strategic execution.
Positive Outlook
- FY25 revenue guidance maintained at $36M–$41M.
- 104% growth in consumables revenue.
- FDA clearance and full release of ClearPoint 3.0 software.
- New long-term credit facility secured.
- Growth across all three key product lines.
Challenges Ahead
- Operating expenses rose 29% due to increased headcount and development costs.
- Free cash flow was negative $6.2 million in Q1.
- Decline in capital equipment sales from $1.4M to $0.5M.
- Lower service revenue from biologics and drug delivery trials.
- No EPS or net income figures disclosed.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...